# **Orbenin-DC** (cloxacillin benzathine intramammary infusion)

## SHORTEST REQUIRED DRY PERIOD WITH ZERO MILK WITHHOLD POST-CALVING.

ORBENIN-DC<sup>™</sup> (cloxacillin benzathine intramammary infusion) delivers targeted treatment of Gram-positive bacteria with the shortest required dry period and no milk withhold. With only a 28-day dry period, fresh cows can move into the milking string faster.

#### Trusted for more than four decades, ORBENIN-DC targets the most common type of subclinical mastitis.

More than 94% of cows with subclinical mastitis at dry-off are infected with Gram-positive bacteria (environmental staphs and streps).<sup>1,2</sup>

# **94%** of all subclinical mastitis infections are Gram-positive.

Gram-negative infections such as *E. coli* usually self-cure during lactation, making ORBENIN-DC an ideal choice at dry-off.

## As effective as leading competitors.<sup>1,2,3</sup>

A non-inferiority study confirmed the efficacy of ORBENIN-DC vs. SPECTRAMAST® DC (ceftiofur hydrochloride) Sterile Suspension. There was no difference between products based on clinical mastitis, somatic cell count, reproductive performance, milk production and cow removal in the next lactation.<sup>4,5</sup>

## Short tip for fewer intramammary infections.

Compared to full insertion, partial insertion has been shown to reduce new infection risk by 50%.<sup>6</sup>

- <sup>1</sup> Johnson AP, et al. Randomized noninferiority study evaluating the efficacy of 2
- commercial dry cow mastitis formulations. *J Dairy Sci.* 2016;99:593-607.
   <sup>2</sup> Aruda AG, et al. Randomized noninferiority clinical trial evaluating 3 commercial dry cow mastitis preparations, Part 1. *J Dairy Sci.* 2013;96:4419-4435.
- <sup>3</sup> Aruda AG, et al. Randomized noninferiority clinical trial evaluating 3 commercial dry cow mastitis preparations, Part 2. *J Dairy Sci.* 2013;96:6390-6399.
   <sup>4</sup> Cox E, et al. Cow-level responses to two commercial dry cow mastitis preparations.
- <sup>4</sup> Cox E, et al. Cow-level responses to two commercial dry cow mastitis preparations. J Dairy Sci. 2017;100:216 (Suppl.2).
- <sup>5</sup> Cow Level Performance of ORBENIN-DC vs. SPECTRAMAST DC in Two Commercial Dairies, Merck Animal Health technical bulletin, 2018.
  <sup>6</sup> Nickerson, SC. Resistance mechanisms of the bovine udder: new implications for
- <sup>6</sup> Nickerson, SC. Resistance mechanisms of the bovine udder: new implications for mastitis control at the teat end. J Am Vet Med Assoc. 1987;191(11):1484-1488.

**ORBENIN-DC:** For use in dry cows only. Do not use within four weeks (28 days) of calving. Treated animals must not be slaughtered for food purposes within 4 weeks (28 days) of treatment. For additional information, see the product label.

**BOVILIS J-5:** This product contains oil adjuvant. In the event of accidental self-injection, seek medical attention immediately. For additional information, see the product label.

All trademarks are property of their respective owners.

# Dry period protection now for a productive future.

The dry period is an important time to minimize mastitis risk and to vaccinate cows to protect their calves from scours. Along with ORBENIN-DC, help protect your herd with the use of:

15.8

- **SHUTOUT™** an internal teat sealant that functions as a physical barrier to help prevent bacterial invasion of the teat canal.
- **BOVILIS® J-5** a Gram-negative core-antigen vaccine that aids in the reduction of mastitis due to *E. coli*.
- **GUARDIAN®** the most complete scours vaccine with the broadest spectrum of protection against the four major bacterial and viral pathogens associated with scours in pre-weaned calves.

#### **DOSAGE & ADMINISTRATION**

- Each 10-mL tube contains 500 mg of cloxacillin.
- Infuse one tube of ORBENIN-DC, warmed to room temperature, into each quarter.
- For complete directions and dosing regimen, refer to the package insert.

## PRESENTATION

• Available in 12-syringe boxes.

#### For more information, talk to your veterinarian or visit OrbeninDC.com.

MAHCattle.com • 800-521-5767

© 2020 Intervet Inc., doing business as Merck Animal Health, a subsidiary of Merck & Co., Inc. All rights reserved. 11/20 US-ORN-201000001





